Диссертация (1139881), страница 15
Текст из файла (страница 15)
Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, PaidasMJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity117and type 2 diabetes mellitus in the mother // Hypertension, 2009, No. 53, pp.944–951.110. Mahan CE, Liu Y, Turpie AG, et al. External validation of a riskassessment model for venous thromboembolism in the hospitalised acutely-illmedical patient (VTE-VALOURR) // Thromb Haemost, 2014, No.
112, pp. 692–699.111. Mahmoodi BK, Cushman M, Anne Næss I, et al. Association ofTraditional Cardiovascular Risk Factors With Venous Thromboembolism: AnIndividual Participant Data Meta-Analysis of Prospective Studies // Circulation,2017, Vol. 135, No. 1, pp. 7-16.112. Mansourati J, Da Costa A, Munier S, Mercier B, Tardy B, Ferec C,Isaaz K, Blanc JJ. Prevalence of factor V Leiden in patients with myocardialinfarction and normal coronary angiography // Thromb Haemost, 2000, No. 83,pp. 822–825.113. Martinelli I, De Stefano V, Mannucci PM. Inherited risk factors forvenous thromboembolism // Nat Rev Cardiol, 2014, Vol. 11, No.
3, pp. 140-56.114. Mathus-Vliegen L, Toouli J, Fried M, Khan AG, Garisch J, Hunt R,Fedail S, Štimac D, Lemair T, Krabshuis J, Kaufmann P, Roberts E, Riccardi G;World Gastroenterology Organization. World Gastroenterology Organisationglobal guidelines on obesity // J Clin Gastroenterol, 2012, Vol. 46, No. 7, pp.555-61.115. McDonnell MN, Hillier SL, Hooker SP, Le A, Judd SE, Howard VJ.Physical activity frequency and risk of incident stroke in a national US study ofblacks and whites // Stroke, 2013, No. 44, pp.
2519–2524.116. Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S,Doggen CJ, Rosendaal FR. Venous thrombosis risk associated with plasmahypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1 //Blood, 2010, Vol.
116, No. 1, pp. 113-21.117. Mensah GA, Brown DW, Croft JB, Greenlund KJ. Major coronaryrisk factors and death from coronary heart disease: baseline and follow-up118mortality data from the Second National Health and Nutrition ExaminationSurvey (NHANES II) // Am J Prev Med, 2005, Vol. 29, No. suppl 1, pp. 68-74.118. Meschia JF, Bushnell C, Boden-Albala B, et al. American HeartAssociation Stroke Council; Council on Cardiovascular and Stroke Nursing;Council on Clinical Cardiology; Council on Functional Genomics andTranslational Biology; Council on Hypertension. Guidelines for the primaryprevention of stroke: a statement for healthcare professionalsfrom the AmericanHeart Association/American Stroke Association // Stroke, 2014, No. 45, pp.3754–3832.119. Middeldorp S. Is thrombophilia testing useful? // Hematology AmSoc Hematol Educ Program, 2011, Vol.
2011, pp. 150-5.120. Mikkelsson J, Perola M, Wartiovaara U, Peltonen L, Palotie A,Penttilä A, Karhunen PJ. Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5GPolymorphism, Coronary Thrombosis, and Myocardial Infarction in Middle-agedFinnish Men who Died Suddenly // Thromb Haemost, 2000, Vol. 84, No. 1, pp.78-82.121. Miñano A, Ordóñez A, España F, González-Porras JR, LecumberriR, Fontcuberta J, Llamas P, Marín F, Estellés A, Alberca I, Vicente V, Corral J.AB0 blood group and risk of venous or arterial thrombosis in carriers of factor VLeiden or prothrombin G20210A polymorphisms // Haematologica, 2008, Vol.93, No. 5, pp.
729-34.122. Morange PE, Henry M, Tregouët D, Granel B, Aillaud MF, AlessiMC, Juhan-Vague I. The A −844G Polymorphism in the PAI-1 Gene IsAssociated With a Higher Risk of Venous Thrombosis in Factor V LeidenCarriers // Arterioscler Thromb Vasc Biol, 2000, Vol. 20, No. 5, pp. 1387-91.123. Morange PE, Saut N, Alessi MC, Yudkin JS, Margaglione M, DiMinno G, Hamsten A, Humphries SE, Tregouet DA, Juhan-Vague I.
Associationof Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With MyocardialInfarction, Plasma PAI-1, and Metabolic Parameters // Arterioscler Thromb VascBiol, 2007, Vol. 27, No. 10, pp. 2250-7.119124. Muller-Buhl U, Leutgeb R, Engeser P, Achankeng EN, Szecsenyi J,Laux G. Varicose veins are a risk factor for deep venous thrombosis in generalpractice patients // Vasa, 2012, No.
41, pp. 360–365.125. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC,Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: apopulation-based study // J Thromb Haemost, 2007, No. 5, pp. 692-699.126. Nakamura K, Barzi F, Lam TH, Huxley R, Feigin VL, Ueshima H,Woo J, Gu D, Ohkubo T, Lawes CM, Suh I, Woodward M; Asia Pacific CohortStudies Collaboration. Cigarette smoking, systolic blood pressure, andcardiovascular diseases in the Asia-Pacific region // Stroke, 2008, No. 39, pp.1694–1702.127. Nendaz MR, Chopard P, Lovis C, Kucher N, Asmis LM, Dörffler J,Spirk D, Bounameaux H.
Adequacy of venous thromboprophylaxis in acutely illmedical patients (IMPART): multisite comparison of different clinical decisionsupport systems // J Thromb Haemost, 2010, Vol. 8, No. 6, pp. 1230-4.128. Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements onthe risk, prevention, and treatment of venous thromboembolism in inflammatorybowel disease: Canadian Association of Gastroenterology // Gastroenterology,2014, No. 146, pp.
835–848.129. Nikolopoulos GK, Bagos PG, Tsangaris I, Tsiara CG, Kopterides P,Vaiopoulos A, Kapsimali V, Bonovas S, Tsantes AE. he association betweenplasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5Gpolymorphism, and myocardial infarction: a Mendelian randomization metaanalysis // Clin Chem Lab Med, 2014, Vol. 52, No. 7, pp. 937-50.130. Noboa S, Le Gal G, Lacut K, Mercier B, Leroyer C, Nowak E,Mottier D, Oger E; EDITH Collaborative Study Group.
Family history as a riskfactor for venous thromboembolism // Thromb Res, 2008, No. 122, pp. 624–629.131. Parpugga TK, Tatarunas V, Skipskis V, Kupstyte N, ZaliaduonytePeksiene D, Lesauskaite V. The Effect of PAI-1 4G/5G Polymorphism and120Clinical Factors on Coronary Artery Occlusion in Myocardial Infarction // DisMarkers, 2015, No. 2015, P. 260101.132. Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematicreview of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries (MINOCA) // Circulation, 2015, Vol.
131, No. 10,pp. 861–870.133. Pasupathy S, Tavella R, Beltrame JF. Myocardial Infarction WithNonobstructive Coronary Arteries (MINOCA): The Past, Present, and FutureManagement // Circulation, 2017, Vol. 135, No. 16, pp. 1490-1493.134. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor forstroke in women compared with men: a systematic review and meta-analysis of64 cohorts, including 775,385 individuals and 12,539 strokes // Lancet, 2014, No.383, pp.
1973–1980.135. Poirier P, Giles TD, Bray GA, et al; American Heart Association;Obesity Committee of the Council on Nutrition, Physical Activity, andMetabolism. Obesity and cardiovascular disease: pathophysiology, evaluation,and effect of weight loss: an update of the 1997 AHA Scientific Statement onObesity and Heart Disease from the Obesity Committee of the Council onNutrition, Physical Activity, and Metaboli // Circulation, 2006, No. 113, pp. 898–918.136. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venousthrombosis: obesity and its joint effect with oral contraceptive use andprothrombotic mutations // Br J Haematol, 2007, Vol. 139, No.
2, pp. 289-96.137. Pomp ER, Rosendaal FR, Doggen CJ. Alcohol consumption isassociated with a decreased risk of venous thrombosis // Thromb Haemost, 2008,Vol. 99, No. 1, pp. 59-63.138. Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk ofvenous thrombosis and acts synergistically with oral contraceptive use // Am JHematol, No. 2008, Vol. 83, No. 2, pp. 97-102.121139.
Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (TakoTsubo or stress cardiomyopathy): a mimic of acute myocardial infarction // AmHeart J, 2008, No. 155, pp. 408–417.140. Prasad A. Apical ballooning syndrome: an important differentialdiagnosis of acute myocardial infarction // Circulation, 2007, No. 115, pp. e56–e59.141. Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factorsfor venous and arterial thrombosis // Blood Transfus, 2011, Vol. 9, No. 2, pp.120–138.142. Prospective Studies Collaboration, Whitlock G, Lewington S,Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R.Body-mass index and cause-specific mortality 20 in 900 000 adults: collaborativeanalyses of 57 prospective studies // Lancet, 2009, No.
373, pp. 1083-96.143. Prospective Studies Collaboration. Cholesterol, diastolic bloodpressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts// Lancet, 1995, No. 346, pp. 1647–1653.144. Rallidis L, Gialeraki A, Tsirebolos G, Drosatos A, Katsimardos A,Pavlakis G, Iliodromitis E. Factor V Leiden and prothrombin G20210A mutationsin patients with premature myocardial infarction // European Heart Journal, 2017,No. 38 (suppl-1), P. 1735.145. Ranellou K, Paraskeva A, Kyriazopoulos P et al.
Polymorphisms inprothrombotic genes in young stroke patients in Greece: a case-controlled study //Blood Coagulation & Fibrinolysis, 2015, Vol. 26, No. 4, pp. 430-435.146. Ray JG, Shmorgun D, Chan WS. Common C677T polymorphism ofthe methylenetetrahydrofolate reductase gene and the risk of venousthromboembolism: meta-analysis of 31 studies // Pathophysiol Haemost Thromb,2002, No. 32, pp. 51-8.147.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
